# Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2013

- Company: [Standard Biotools Inc.](/companies/lab.md) (CIK 1162194)
- Form: 10-Q
- Filed: 2013-11-07
- Accepted by EDGAR: Nov 7, 2013, 17:27 ET
- Period: 2013-09-30
- Accession: 0001445305-13-002845
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1162194/000144530513002845/q32013form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1162194/000144530513002845/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-07-01 to 2013-09-30 | $18.3m | us-gaap:Revenues |
| Revenue | 9 months, 2013-01-01 to 2013-09-30 | $50.3m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2013-07-01 to 2013-09-30 | $5.1m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2013-01-01 to 2013-09-30 | $14.3m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2013-07-01 to 2013-09-30 | $5.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2013-01-01 to 2013-09-30 | $14.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2013-07-01 to 2013-09-30 | $12.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2013-01-01 to 2013-09-30 | $34.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2013-07-01 to 2013-09-30 | −$5.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2013-01-01 to 2013-09-30 | −$14.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-07-01 to 2013-09-30 | $1.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2013-01-01 to 2013-09-30 | $13.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2013-07-01 to 2013-09-30 | $42.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2013-01-01 to 2013-09-30 | $95.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-07-01 to 2013-09-30 | −$4.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2013-01-01 to 2013-09-30 | −$11.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-07-01 to 2013-09-30 | −$0.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2013-01-01 to 2013-09-30 | −$0.47 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2013-01-01 to 2013-09-30 | −$4.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2013-01-01 to 2013-09-30 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2013-09-30 | $20.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-09-30 | $86.7m | us-gaap:AssetsCurrent |
| Total assets | at 2013-09-30 | $114.2m | us-gaap:Assets |
| Current liabilities | at 2013-09-30 | $15.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-09-30 | $17.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2013-09-30 | $97.0m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1162194/000144530513002845/q32013form10-q.htm

Filed Nov 7, 2013.
Source: SEC EDGAR, the filing index for accession 0001445305-13-002845. Last ingested by Listed: Nov 5, 2026, 21:16 ET. No prices; not investment advice.
